| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab176565-100μg |
100μg |
现货  |
| |
| Ab176565-1mg |
1mg |
现货 |
| |
| Ab176565-5mg |
5mg |
现货 |
| |
| Ab176565-10mg |
10mg |
期货 |
|
| 产品名称 | LY3076226 (anti-FGFR3) |
|---|---|
| 别名 | ACH antibody | CD 333 antibody | CD333 antibody | CD333 antigen antibody | CEK 2 antibody | CEK2 antibody | FGFR 3 antibody | FGFR-3 antibody | FGFR3 antibody | FGFR3_HUMAN antibody | Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarf |
| 英文别名 | EC 2.7.10.1 | FGFR-3 |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | FGFR3 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | lambdaC2 |
| SDS-PAGE | 145.78 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| 分子类型 | 抗体 |
LY3076226 (anti-FGFR3) (Ab176565) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling FGFR3 (red) with LY3076226 (anti-FGFR3) (Ab176565). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
LY3076226 (anti-FGFR3) (Ab176565) - SEC
The purity of LY3076226 (anti-FGFR3) (Ab176565) is more than 95% verified by HPLC.
LY3076226 (anti-FGFR3) (Ab176565) - ELISA
Immobilized FGFR3-chis a at 2.0 μg/mL can bind LY3076226 (anti-FGFR3) (Ab176565) with the EC₅₀ of 8.06 ng/mL.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0911495 |
分析证书 | 24-09-30 | Ab176565 |
| ZJ24F0911496 |
分析证书 | 24-09-30 | Ab176565 |
| ZJ24F0911498 |
分析证书 | 24-09-30 | Ab176565 |
| ZJ23F1201927 |
分析证书 | 23-12-06 | Ab176565 |
| ZJ23F1201928 |
分析证书 | 23-12-06 | Ab176565 |
¥739.90
| 1. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.. (1998) Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.. J Med Chem, 41 (5): (742-751). [PMID:9513602] [10.1021/jm970641d] |
| 2. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433] |
| 3. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Mohammadi M. (2004) Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.. Proc Natl Acad Sci USA, 101 (4): (935-40). [PMID:14732692] |
| 4. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al.. (2010) A structure-guided approach to creating covalent FGFR inhibitors.. Chem Biol, 17 (3): (285-95). [PMID:20338520] |
| 5. Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, Pfeifer SP, McVean GA, Rajpert-De Meyts E, Wilkie AO. (2009) Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.. Nat Genet, 41 (11): (1247-52). [PMID:19855393] |
| 6. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, Bergsagel PL. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.. Nat Genet, 16 (3): (260-4). [PMID:9207791] |
| 7. Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA et al.. (2006) Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.. J Med Chem, 49 (4): (1475-85). [PMID:16480284] |
| 8. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099] |
| 9. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568] |
| 10. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.. Cancer Res, 70 (4): (1524-33). [PMID:20145145] |
| 11. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.. Blood, 105 (7): (2941-8). [PMID:15598814] |
| 12. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, Zia-Ebrahimi M, Bloem L, Zhai Y, Huss K et al.. (2011) A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.. Mol Cancer Ther, 10 (11): (2200-10). [PMID:21900693] |
| 13. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238] |
| 14. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al.. (2002) Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.. J Med Chem, 45 (17): (3772-93). [PMID:12166950] |
| 15. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921] |
| 16. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 42 (26): (5369-89). [PMID:10639280] |
| 17. Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N et al.. (2015) First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.. Cancer Discov, 5 (4): (424-37). [PMID:25776529] |
| 18. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640] |
| 19. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G. (2016) Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.. PLoS ONE, 11 (9): (e0162594). [PMID:27627808] |
| 20. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al.. (2017) Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.. J Med Chem, 60 (15): (6516-6527). [PMID:28665128] |
| 21. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898] |
| 22. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al.. (2019) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy.. J Med Chem, 62 (14): (6665-6681). [PMID:31095385] |
| 23. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al.. (2013) Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.. J Med Chem, 56 (3): (879-94). [PMID:23301703] |
| 24. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.. J Biol Chem, 282 (37): (26687-26695). [PMID:17623664] |
| 25. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.. Bioorg Med Chem Lett, 14 (13): (3601-3605). [PMID:15177483] [10.1016/j.bmcl.2004.03.111] |
| 26. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.. (2005) Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.. J Med Chem, 48 (12): (3991-4008). [PMID:15943473] [10.1021/jm0501275] |
| 27. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.. (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.. J Med Chem, 48 (7): (2371-2387). [PMID:15801830] [10.1021/jm049355+] |
| 28. Vendôme J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C, Le Bret M.. (2005) Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.. J Med Chem, 48 (20): (6194-6201). [PMID:16190746] [10.1021/jm050231m] |
| 29. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.. (2006) Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.. Bioorg Med Chem Lett, 16 (2): (262-266). [PMID:16249085] [10.1016/j.bmcl.2005.10.015] |
| 30. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y.. (2006) Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.. Bioorg Med Chem Lett, 16 (7): (1950-1953). [PMID:16460940] [10.1016/j.bmcl.2005.12.092] |
| 31. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H.. (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.. J Med Chem, 50 (18): (4351-4373). [PMID:17696416] [10.1021/jm070034i] |
| 32. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.. J Med Chem, 50 (23): (5579-5588). [PMID:17929792] [10.1021/jm061449r] |
| 33. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104] |
| 34. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T.. (2010) A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.. J Med Chem, 53 (15): (5439-5448). [PMID:20604564] [10.1021/jm901808w] |
| 35. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM.. (2011) Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.. Bioorg Med Chem, 19 (6): (1915-1923). [PMID:21353571] [10.1016/j.bmc.2011.01.067] |
| 36. Kim H, Kim M, Lee J, Yu H, Hah JM.. (2011) Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.. Bioorg Med Chem, 19 (22): (6760-6767). [PMID:22014755] [10.1016/j.bmc.2011.09.042] |
| 37. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634] |
| 38. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G.. (2012) VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.. J Med Chem, 55 (2): (725-734). [PMID:22221201] [10.1021/jm201198w] |
| 39. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818] [10.1021/jm300309a] |
| 40. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479] [10.1016/j.bmcl.2012.10.016] |
| 41. Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, Jouannigot N, Deprez P, van der Aar EM, Clement-Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, Brys R, Uhring M, Ciesielski F, Van Rompaey L.. (2014) Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.. J Med Chem, 57 (22): (9323-9342). [PMID:25369270] [10.1021/jm501262q] |
| 42. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.. (2015) Nintedanib: from discovery to the clinic.. J Med Chem, 58 (3): (1053-1063). [PMID:25474320] [10.1021/jm501562a] |
| 43. Abdel-Magid AF.. (2015) Fibroblast Growth Factor Receptor 3 (FGF-R3): A Promising Therapeutic Target for the Treatment of Bladder Cancer.. ACS Med Chem Lett, 6 (4): (369-370). [PMID:25941550] [10.1021/acsmedchemlett.5b00078] |
| 44. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099] |
| 45. Fan J, Dai Y, Shao J, Peng X, Wang C, Cao S, Zhao B, Ai J, Geng M, Duan W.. (2016) Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.. Bioorg Med Chem Lett, 26 (11): (2594-2599). [PMID:27117427] [10.1016/j.bmcl.2016.04.028] |
| 46. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079] |
| 47. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076] |
| 48. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.. (2018) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.. J Med Chem, 61 (1): (140-157). [PMID:29189002] [10.1021/acs.jmedchem.7b01091] |
| 49. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031] |
| 50. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020] |
| 51. Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L.. (2019) Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.. Eur J Med Chem, 184 (111710-111710). [PMID:31614258] [10.1016/j.ejmech.2019.111710] |
| 52. Lin X, Yosaatmadja Y, Kalyukina M, Middleditch MJ, Zhang Z, Lu X, Ding K, Patterson AV, Smaill JB, Squire CJ.. (2019) Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.. ACS Med Chem Lett, 10 (8): (1180-1186). [PMID:31413803] [10.1021/acsmedchemlett.9b00196] |
| 53. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843] |
| 54. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (309-329). [PMID:31096153] [10.1016/j.ejmech.2019.04.035] |
| 55. Lu X, Chen H, Patterson AV, Smaill JB, Ding K.. (2019) Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.. J Med Chem, 62 (6): (2905-2915). [PMID:30403487] [10.1021/acs.jmedchem.8b01531] |
| 56. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015] |
| 57. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006] |
| 58. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564] [10.1021/acsmedchemlett.0c00015] |
| 59. Kuriwaki I, Kameda M, Hisamichi H, Kikuchi S, Iikubo K, Kawamoto Y, Moritomo H, Kondoh Y, Amano Y, Tateishi Y, Echizen Y, Iwai Y, Noda A, Tomiyama H, Suzuki T, Hirano M.. (2020) Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.. Bioorg Med Chem, 28 (10): (115453-115453). [PMID:32278710] [10.1016/j.bmc.2020.115453] |
| 60. Rezende Miranda R,Fu Y,Chen X,Perino J,Cao P,Carpten J,Chen Y,Zhang C. (2020) Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma.. J Med Chem, 63 (20): (11484-11497). [PMID:33030342] [10.1021/acs.jmedchem.0c00044] |
| 61. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P. (2020) Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.. J Med Chem, 63 (21.0): (12542-12573). [PMID:32930584] [10.1021/acs.jmedchem.0c01019] |
| 62. Kuriwaki I,Kameda M,Iikubo K,Hisamichi H,Kawamoto Y,Kikuchi S,Moritomo H,Kondoh Y,Terasaka T,Amano Y,Tateishi Y,Echizen Y,Iwai Y,Noda A,Tomiyama H,Nakazawa T,Hirano M. (2021) Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.. Bioorg Med Chem, 33 (116019-116019). [PMID:33486159] [10.1016/j.bmc.2021.116019] |
| 63. Chen X,Liu Y,Zhang L,Chen D,Dong Z,Zhao C,Liu Z,Xia Q,Wu J,Chen Y,Zheng X,Cai Y. (2021) Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.. Eur J Med Chem, 214 (113219-113219). [PMID:33618175] [10.1016/j.ejmech.2021.113219] |
| 64. Thompson, L M LM and 6 more authors.. (1991) A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4.. Genomics, [PMID:1664411] |
| 65. Keegan, K K, Johnson, D E DE, Williams, L T LT and Hayman, M J MJ.. (1991) Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:1847508] |
| 66. Partanen, J J, Mäkelä, T P TP, Alitalo, R R, Lehväslaiho, H H and Alitalo, K K.. (1990) Putative tyrosine kinases expressed in K-562 human leukemia cells.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2247464] |
| 67. Meyers, G A GA, Orlow, S J SJ, Munro, I R IR, Przylepa, K A KA and Jabs, E W EW.. (1995) Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.. Nature genetics, [PMID:7493034] |
| 68. Scotet, E E and Houssaint, E E.. (1995) The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific.. Biochimica et biophysica acta, (7): [PMID:7495869] |
| 69. Bellus, G A GA and 8 more authors.. (1995) A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.. Nature genetics, [PMID:7670477] |
| 70. Superti-Furga, A A and 6 more authors.. (1995) A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia.. European journal of pediatrics, [PMID:7758520] |
| 71. Tavormina, P L PL and 9 more authors.. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.. Nature genetics, [PMID:7773297] |
| 72. Bellus, G A GA and 8 more authors.. (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3.. American journal of human genetics, [PMID:7847369] |
| 73. Murgue, B B, Tsunekawa, S S, Rosenberg, I I, deBeaumont, M M and Podolsky, D K DK.. (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.. Cancer research, (1): [PMID:7923141] |
| 74. Tavormina, P L PL and 5 more authors.. (1995) Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I.. Human molecular genetics, [PMID:8589699] |
| 75. Webster, M K MK and Donoghue, D J DJ.. (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.. The EMBO journal, (1): [PMID:8599935] |
| 76. Webster, M K MK, D'Avis, P Y PY, Robertson, S C SC and Donoghue, D J DJ.. (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.. Molecular and cellular biology, [PMID:8754806] |
| 77. Rousseau, F F and 6 more authors.. (1996) Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).. Human molecular genetics, [PMID:8845844] |
| 78. Muenke, M M and 24 more authors.. (1997) A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome.. American journal of human genetics, [PMID:9042914] |
| 79. Deutz-Terlouw, P P PP, Losekoot, M M, Aalfs, C M CM, Hennekam, R C RC and Bakker, E E.. (1998) Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia.. Human mutation, [PMID:9452043] |
| 80. Hollway, G E GE and 5 more authors.. (1998) Deafness due to Pro250Arg mutation of FGFR3.. Lancet (London, England), (21): [PMID:9525367] |
| 81. Katsumata, N N and 7 more authors.. (1998) G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.. Endocrine journal, [PMID:9790257] |
| 82. Lajeunie, E E and 5 more authors.. (1999) Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation.. Journal of medical genetics, [PMID:9950359] |
| 83. Tavormina, P L PL and 13 more authors.. (1999) A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.. American journal of human genetics, [PMID:10053006] |
| 84. Grigelioniené, G G and 5 more authors.. (1998) A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online.. Human mutation, [PMID:10215410] |
| 85. Brodie, S G SG and 5 more authors.. (1999) Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.. American journal of medical genetics, (11): [PMID:10360402] |
| 86. Cappellen, D D and 8 more authors.. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.. Nature genetics, [PMID:10471491] |
| 87. Monsonego-Ornan, E E, Adar, R R, Feferman, T T, Segev, O O and Yayon, A A.. (2000) The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.. Molecular and cellular biology, [PMID:10611230] |
| 88. Kitoh, H H, Brodie, S G SG, Kupke, K G KG, Lachman, R S RS and Wilcox, W R WR.. (1998) Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online.. Human mutation, [PMID:10671061] |
| 89. Mortier, G G and 5 more authors.. (2000) Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene.. Journal of medical genetics, [PMID:10777366] |
| 90. Bellus, G A GA and 10 more authors.. (2000) Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.. American journal of human genetics, [PMID:11055896] |
| 91. Hart, K C KC, Robertson, S C SC and Donoghue, D J DJ.. (2001) Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.. Molecular biology of the cell, [PMID:11294897] |
| 92. Sibley, K K, Cuthbert-Heavens, D D and Knowles, M A MA.. (2001) Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.. Oncogene, (8): [PMID:11314002] |
| 93. Jang, J H JH, Shin, K H KH and Park, J G JG.. (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.. Cancer research, (1): [PMID:11325814] |
| 94. Intini, D D and 6 more authors.. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).. British journal of haematology, [PMID:11529856] |
| 95. Terada, M M and 5 more authors.. (2001) Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs.. Molecular cell biology research communications : MCBRC, [PMID:11703096] |
| 96. Lowry, R B RB, Jabs, E W EW, Graham, G E GE, Gerritsen, J J and Fleming, J J.. (2001) Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel shoulder with and without Pro250Arg mutation in the FGFR3 gene.. American journal of medical genetics, (22): [PMID:11746040] |
| 97. Monsonego-Ornan, E E, Adar, R R, Rom, E E and Yayon, A A.. (2002) FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation.. FEBS letters, (25): [PMID:12297284] |
| 98. Thauvin-Robinet, Christel C and 9 more authors.. (2003) Hypochondroplasia and stature within normal limits: another family with an Asn540Ser mutation in the fibroblast growth factor receptor 3 gene.. American journal of medical genetics. Part A, (15): [PMID:12707965] |
| 99. Agazie, Yehenew M YM, Movilla, Nieves N, Ischenko, Irene I and Hayman, Michael J MJ.. (2003) The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.. Oncogene, (9): [PMID:14534538] |
| 100. L'Hôte, Corine G M CG and Knowles, Margaret A MA.. (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.. Experimental cell research, (1): [PMID:15748888] |
| 101. Logié, Armelle A and 11 more authors.. (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.. Human molecular genetics, (1): [PMID:15772091] |
| 102. Eswarakumar, V P VP, Lax, I I and Schlessinger, J J.. (2005) Cellular signaling by fibroblast growth factor receptors.. Cytokine & growth factor reviews, [PMID:15863030] |
| 103. Ben-Zvi, Tal T, Yayon, Avner A, Gertler, Arieh A and Monsonego-Ornan, Efrat E.. (2006) Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling.. Journal of cell science, (15): [PMID:16410555] |
| 104. Rohmann, Edyta E and 21 more authors.. (2006) Mutations in different components of FGF signaling in LADD syndrome.. Nature genetics, [PMID:16501574] |
| 105. Zhang, Xiuqin X and 5 more authors.. (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.. The Journal of biological chemistry, (9): [PMID:16597617] |
| 106. Hafner, Christian C and 8 more authors.. (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.. The Journal of clinical investigation, [PMID:16841094] |
| 107. Toydemir, Reha M RM and 9 more authors.. (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.. American journal of human genetics, [PMID:17033969] |
| 108. Krejci, Pavel P and 6 more authors.. (2007) Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.. The Journal of biological chemistry, (2): [PMID:17145761] |
| 109. Bonaventure, Jacky J, Gibbs, Linda L, Horne, William C WC and Baron, Roland R.. (2007) The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.. The FEBS journal, [PMID:17509076] |
| 110. Harada, Daisuke D and 6 more authors.. (2007) Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.. Bone, [PMID:17561467] |
| 111. Arnaud-López, L L, Fragoso, R R, Mantilla-Capacho, J J and Barros-Núñez, P P.. (2007) Crouzon with acanthosis nigricans. Further delineation of the syndrome.. Clinical genetics, [PMID:17935505] |
| 112. Matsui, Junji J and 7 more authors.. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.. International journal of cancer, (1): [PMID:17943726] |
| 113. Krejci, Pavel P and 8 more authors.. (2008) Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.. PloS one, [PMID:19088846] |
| 114. Salazar, Lisa L and 6 more authors.. (2009) A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.. Human molecular genetics, (1): [PMID:19286672] |
| 115. Gozgit, Joseph M JM and 9 more authors.. (2013) Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.. Cancer chemotherapy and pharmacology, [PMID:23468082] |
| 116. Tabernero, Josep J and 18 more authors.. (2015) Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (20): [PMID:26324363] |
| 117. Rousseau, F F and 7 more authors.. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.. Nature, (15): [PMID:8078586] |
首页
400-620-6333
